Corticotropin-Releasing Hormone
What the Research Actually Shows
Human: 0 studies, 4 groups · Animal: 1 · In Vitro: 0
The 41-amino-acid peptide that tells your body it is time to be stressed—discovered in 1981 by a Nobel-caliber scientist, proven central to depression and PTSD biology, and the target of a billion-dollar drug development failure that no one saw coming
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
CRH is the hormone that starts your stress response. When your brain detects a threat, CRH fires first—triggering the chain reaction that ends in cortisol flooding your bloodstream. In people with depression, CRH levels in spinal fluid are abnormally high. In people with PTSD, the CRH-driven stress system is stuck in overdrive. The science linking CRH to stress disorders is among the strongest in neuroscience. Drug companies spent decades and hundreds of millions of dollars trying to develop CRH-blocking drugs for depression and anxiety. Every one of them failed in clinical trials. CRH is FDA-approved as a diagnostic test—not as a treatment. No one takes CRH as a supplement. The biology is bulletproof. The therapeutic translation is zero.
Corticotropin-releasing hormone sits at the apex of the stress response. When the hypothalamus perceives threat—physical, psychological, or metabolic—a cluster of neurons in the paraventricular nucleus releases CRH into the blood vessels connecting the brain to the pituitary gland. CRH binds receptors on pituitary corticotrope cells, triggering ACTH release, which in turn drives cortisol production from the adrenal cortex. This hypothalamic-pituitary-adrenal (HPA) axis cascade is the best-characterized neuroendocrine pathway in human biology, and CRH is the molecule that starts it.
The clinical relevance of CRH to Cluster J—Sleep, Stress & Recovery—is direct. CRH is arousal-promoting: it increases wakefulness, disrupts slow-wave sleep, and contributes to the insomnia that characterizes depression and PTSD. It is the physiological antagonist of neuropeptide Y (also in this cluster), which dampens the stress response that CRH initiates. In healthy physiology, CRH and NPY exist in dynamic balance. In stress disorders, CRH wins—and the consequences are measurable in spinal fluid, blood cortisol, and disrupted sleep architecture.
The discovery of elevated CRH in depression (Nemeroff et al., 1984; PMID 6581756) launched one of the largest drug development efforts in psychiatric history. Multiple pharmaceutical companies developed CRH receptor type 1 (CRH-R1) antagonists—drugs designed to block CRH signaling as a treatment for depression and anxiety. Every one failed to demonstrate consistent efficacy in clinical trials (Holsboer & Ising, 2010; PMID 20594304). This article examines what CRH does, why the biology is so convincing, and why blocking the most obvious drug target in stress biology has proven so difficult.
In This Article
Quick Facts: Corticotropin-Releasing Hormone at a Glance
Type
Endogenous neuropeptide, 41 amino acids, linear peptide
Also Known As
CRF (corticotropin-releasing factor), corticoliberin, CRH-41
Generic Name
Corticorelin ovine triflutate (diagnostic formulation, brand name Acthrel). No therapeutic CRH or CRH antagonist approved.
Route
IV bolus (diagnostic CRH stimulation test). Not administered therapeutically. No subcutaneous, oral, or intranasal protocols. Peptide community: not applicable.
Molecular Weight
~4,758 Da
Peptide Sequence
41-amino-acid linear peptide. Human CRH: Ser-Glu-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Met-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-Leu-Met-Glu-Ile-Ile-NH₂.
Endogenous Origin
Yes. Produced primarily in the paraventricular nucleus (PVN) of the hypothalamus. Also expressed in the central nucleus of the amygdala (fear/anxiety circuitry), cerebral cortex, and peripheral tissues including gut, skin, and immune cells.
Primary Molecular Function
Binds CRH-R1 on anterior pituitary corticotropes → adenylate cyclase → cAMP → proopiomelanocortin (POMC) cleavage → ACTH release → adrenal cortisol production. Also directly activates amygdala stress and fear circuits independent of the HPA axis.
Active Fragment
Full-length CRH (1–41) is the primary active form. Urocortins (Ucn I, II, III) are CRH family members with different receptor selectivity: Ucn I binds both CRH-R1 and CRH-R2; Ucn II and III are CRH-R2 selective.
Brand Name
Acthrel (diagnostic CRH, corticorelin ovine triflutate). Used to differentiate pituitary vs. ectopic ACTH sources in Cushing's syndrome.
Related Compound Relationship
Physiological antagonist of neuropeptide Y (NPY, also in Cluster J)—CRH activates the stress axis while NPY dampens it. Cosyntropin (ACTH 1–24, also in Cluster J) is CRH's downstream effector—CRH triggers ACTH release. Urocortins are CRH family members with overlapping but distinct receptor profiles.
Clinical Programs
No active therapeutic programs for CRH agonists or antagonists. Failed programs: pexacerfont (CRH-R1 antagonist, Phase II anxiety/PTSD—failed), verucerfont (CRH-R1, Phase II—abandoned), CP-154,526 (hepatotoxicity), antalarmin (preclinical tool only). The graveyard of CRH1 antagonists is one of psychiatry's most expensive failures.
WADA Status
Not on the Prohibited List
Community Interest
None. CRH is not sold by peptide vendors and would be counterproductive to administer—it activates the stress response. The interest is in blocking CRH, not supplementing it. Academic and biohacking discussions of CRH are conceptual (understanding stress biology), not practical.
FDA Status
Corticorelin ovine triflutate (Acthrel): FDA-approved as a DIAGNOSTIC agent for Cushing's syndrome workup. No CRH receptor antagonist has achieved FDA approval for any therapeutic indication.
Half-Life
Plasma: ~5–15 minutes. CRH is rapidly cleared by enzymatic degradation. The short half-life is why the diagnostic CRH stimulation test uses IV bolus administration with timed blood draws over 60 minutes.
Evidence Tier
4 Preclinical Only
Verdict
Eyes Open
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is CRH?
Pronunciation: see-are-aitch (corticotropin-releasing HORMONE)
In 1981, Wylie Vale and his team at the Salk Institute ended a 26-year hunt. Since 1955, neuroendocrinologists had known that something in the hypothalamus told the pituitary to release ACTH—the hormone that drives cortisol production—but no one could isolate it. Vale's group extracted CRH from 500,000 sheep hypothalami, sequenced its 41 amino acids, and identified the molecule that starts the human stress response (Vale et al., 1981; PMID 6272306). The discovery was considered Nobel-caliber and transformed the field of stress biology overnight.
CRH is not merely a stress hormone—it is the stress hormone's trigger. When your brain detects threat, danger, pain, or physiological disruption, neurons in the paraventricular nucleus of the hypothalamus release CRH into the hypophyseal portal system—a dedicated vascular highway between the hypothalamus and pituitary. CRH binds CRH-R1 receptors on pituitary corticotrope cells, initiating the cascade: CRH → ACTH → cortisol. This hypothalamic-pituitary-adrenal (HPA) axis is the master regulator of the mammalian stress response, and CRH is the first domino.
But CRH does more than trigger cortisol. It acts directly in the amygdala—the brain's fear-processing center—to promote anxiety and fear behaviors independent of cortisol. It disrupts sleep by promoting arousal and suppressing slow-wave sleep. It modulates immune function, gut motility, and appetite. CRH is less a single-function hormone and more of a body-wide alarm system that coordinates the organism's response to threat across every physiological domain.
PLAIN ENGLISH
CRH is the molecule that fires the starting gun on your stress response. When your brain senses danger, CRH triggers a chain reaction that ends with cortisol flooding your bloodstream—the hormone that raises blood sugar, speeds your heart, and sharpens your focus. CRH also acts directly on your brain's fear center and disrupts deep sleep. It took scientists 26 years and half a million sheep brains to find it.
Origins and Discovery
The search for CRH began in 1955, when Geoffrey Harris proposed that the hypothalamus controlled pituitary hormone release through chemical messengers—not direct neural connections. Roger Guillemin and Andrew Schally, who would share the 1977 Nobel Prize for isolating other hypothalamic releasing hormones (TRH, GnRH, somatostatin), both attempted to isolate CRH and failed. The peptide was present in vanishingly small quantities and degraded rapidly during extraction.
Wylie Vale succeeded where others failed through a combination of improved extraction techniques and immunoassay-guided purification. His 1981 paper reported the isolation and characterization of a 41-amino-acid peptide from ovine hypothalamic extracts that potently stimulated ACTH release from cultured pituitary cells. The peptide was sequenced, synthesized, and confirmed as the long-sought corticotropin-releasing factor. The human form was subsequently cloned and found to differ from the ovine sequence by seven amino acids—but with identical biological activity.
The discovery triggered an explosion of research. Within a decade, CRH-R1 and CRH-R2 receptors were identified and cloned. The CRH family expanded to include urocortins I, II, and III—related peptides with different receptor selectivity profiles. And Charles Nemeroff's 1984 finding that CSF CRH was elevated in major depression (PMID 6581756) turned CRH from a neuroendocrine curiosity into a potential psychiatric drug target—launching the pharmaceutical industry's most expensive failed bet in stress biology.
PLAIN ENGLISH
Scientists knew since the 1950s that something in the brain told the pituitary to release stress hormones, but it took until 1981 to find it. Wylie Vale extracted CRH from half a million sheep brains at the Salk Institute. Three years later, another team discovered that depressed people have too much CRH in their spinal fluid. That finding convinced drug companies to spend billions trying to develop CRH-blocking drugs. None of them worked.
Mechanism of Action
The HPA Axis Cascade
CRH's primary mechanism is the initiation of the hypothalamic-pituitary-adrenal axis—the most thoroughly characterized neuroendocrine pathway in human biology:
Step 1 — CRH release: Stress signals from the amygdala, prefrontal cortex, brainstem, and peripheral afferents converge on CRH-producing neurons in the paraventricular nucleus (PVN) of the hypothalamus. These neurons release CRH (and the co-secretagogue arginine vasopressin) into the hypophyseal portal capillaries—a dedicated vascular connection to the anterior pituitary.
Step 2 — ACTH release: CRH binds CRH-R1 on anterior pituitary corticotrope cells. CRH-R1 is a Gs-coupled receptor: activation → adenylate cyclase → cAMP → protein kinase A → POMC gene transcription and peptide processing → ACTH secretion into systemic circulation. AVP potentiates this effect through V1b receptors on the same cells.
Step 3 — Cortisol production: Circulating ACTH binds MC2R receptors on adrenal zona fasciculata cells → steroidogenesis → cortisol release. Cortisol is the primary effector hormone of the stress response, with effects spanning gluconeogenesis, immune suppression, cardiovascular tone, and cognitive function.
Step 4 — Negative feedback: Cortisol acts on glucocorticoid receptors in the PVN and hippocampus to suppress CRH release, completing the feedback loop. In healthy physiology, this feedback terminates the stress response within hours. In depression, this feedback is impaired—CRH remains elevated, and the axis stays active.
Extra-Hypothalamic CRH — The Fear Circuit
CRH's role extends beyond the HPA axis. CRH-R1 receptors in the central nucleus of the amygdala and the bed nucleus of the stria terminalis (BNST) mediate anxiety and fear behaviors independently of cortisol. This "behavioral" CRH system activates in parallel with the "endocrine" HPA system: you feel afraid (amygdala CRH) and produce cortisol (hypothalamic CRH) simultaneously but through different pathways.
This distinction matters because it explains why simply blocking cortisol does not treat anxiety—you would need to block amygdala CRH signaling as well. The CRH-R1 antagonists that failed in clinical trials were designed to block both pathways simultaneously.
CRH and Sleep
CRH is a potent arousal promoter. Intracerebroventricular CRH administration in animals produces dose-dependent increases in wakefulness and reductions in slow-wave sleep (SWS). Elevated CRH in depression correlates with the classic sleep architecture disruption of major depression: reduced SWS, shortened REM latency, increased REM density. NPY—CRH's physiological counterweight—promotes SWS and opposes CRH-induced arousal. The CRH/NPY balance in the hypothalamus is increasingly recognized as a key determinant of sleep quality under stress.
PLAIN ENGLISH
CRH works like a fire alarm for your body. When your brain detects danger, CRH triggers a chain reaction: CRH → ACTH → cortisol. That same alarm also fires directly in your brain's fear center, making you feel anxious independently of cortisol. And CRH promotes wakefulness while suppressing deep sleep—which is why stressed and depressed people often sleep poorly. NPY (covered elsewhere in this cluster) acts as CRH's off switch. When the balance between them tilts toward CRH, the stress system runs hot.
Key Research Areas and Studies
The Discovery (Vale et al., 1981)
Study: Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. PMID: 6272306 Significance: The discovery paper. Ended a 26-year search. Identified the 41-amino-acid peptide that initiates the HPA axis. Enabled every subsequent study of CRH in stress, depression, and anxiety.
CSF CRH Elevation in Depression (Nemeroff et al., 1984)
Study: Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. PMID: 6581756 Design: CSF sampling in 54 subjects (23 depressed, 31 controls). Key findings: Depressed patients had significantly elevated CSF CRH concentrations compared to healthy controls and neurological disease controls. CSF CRH correlated with HPA axis hyperactivity. Significance: This paper launched the CRH hypothesis of depression—the idea that excess CRH drives depressive symptoms through HPA axis hyperactivation and direct behavioral effects. It became one of the most cited papers in biological psychiatry and the scientific rationale for CRH-R1 antagonist drug development.
The Failure of CRH-R1 Antagonists (Holsboer & Ising, 2010)
Study: Stress hormone regulation: biological role and translation into therapy. PMID: 20594304 Scope: Comprehensive review of CRH-R1 antagonist clinical development. Key findings: Despite strong preclinical data and compelling rationale, no CRH-R1 antagonist demonstrated consistent efficacy in clinical trials for depression or anxiety. Pexacerfont failed a Phase III anxiety trial. Verucerfont was discontinued. Early compounds (CP-154,526) showed hepatotoxicity. The field largely abandoned CRH-R1 antagonism as a therapeutic strategy. Why they failed (proposed explanations): - Depression is biologically heterogeneous—only a subpopulation has CRH-driven HPA axis dysregulation - CRH-R1 blockade may need to be combined with CRH-R2 modulation - Trial designs may not have selected for CRH-overactive patients - Compensatory mechanisms (urocortins, AVP) may maintain HPA axis activity despite CRH-R1 blockade - The clinical trial endpoint (symptom reduction over 6–8 weeks) may not capture CRH-R1 antagonist benefits, which could require longer treatment or different outcome measures
CRH and Anxiety Disorders (Risbrough & Stein, 2006)
Study: Role of corticotropin releasing factor in anxiety disorders: a translational research perspective. PMID: 16814282 Scope: Review of CRH involvement in anxiety, panic, PTSD, and phobia. Key findings: CRH-R1 overactivation is implicated in fear conditioning, stress sensitization, and anxiety maintenance. CRH-R1 knockout mice show reduced anxiety. CRH overexpressing mice show chronic anxiety phenotype. The translational gap between these robust preclinical findings and the clinical trial failures remains unexplained.
PLAIN ENGLISH
CRH's story is one of the great puzzles in medicine. The discovery in 1981 identified the molecule that starts the stress response. The 1984 finding that depressed people have too much CRH in their spinal fluid pointed directly at a drug target. Multiple pharmaceutical companies developed drugs to block CRH receptors. Every one failed in clinical trials. The leading explanation is that depression is too biologically diverse—CRH excess may drive some cases but not all—and the trials tested CRH blockers on all depressed patients rather than selecting for the subset with CRH overactivity.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “CRH causes the stress response” | CRH initiates the HPA axis cascade: CRH → ACTH → cortisol. This is among the most thoroughly proven mechanisms in endocrinology, established in humans through decades of research. | Supported |
| “Excess CRH causes depression” | CSF CRH is elevated in major depression (Nemeroff et al., 1984, PMID 6581756). Correlation established in multiple studies. But CRH-R1 antagonists did not treat depression in clinical trials—suggesting CRH excess is involved in, but not sufficient to explain, depression. | Mixed Evidence |
| “Blocking CRH receptors treats depression” | Multiple CRH-R1 antagonists failed Phase II/III trials for depression and anxiety disorders (Holsboer & Ising, 2010, PMID 20594304). The most expensive therapeutic hypothesis in stress biology did not translate clinically. | Unsupported |
| “CRH disrupts sleep” | CRH promotes arousal and reduces slow-wave sleep in animal models. Sleep disruption in depression correlates with CRH elevation. No human intervention study has tested CRH modulation specifically for sleep. | Mixed Evidence |
| “CRH is elevated in PTSD” | CSF CRH is elevated in combat-related PTSD. CRH-R1 overactivation in the amygdala is implicated in fear conditioning and anxiety maintenance. Multiple correlational studies support this. | Supported |
| “CRH antagonists could treat PTSD” | Preclinical evidence is strong (CRH-R1 knockout mice show reduced fear). Clinical data is essentially nonexistent—no completed Phase II PTSD trial of a CRH-R1 antagonist with adequate power. | Preclinical Only |
| “CRH testing can diagnose Cushing's” | Corticorelin ovine triflutate (Acthrel) is FDA-approved for differentiating pituitary-dependent vs. ectopic ACTH-producing Cushing's syndrome. Established diagnostic tool. | Supported |
| “Taking CRH supplements helps with stress” | This is backwards. CRH activates the stress response—exogenous CRH would increase stress, not reduce it. No one administers CRH therapeutically for stress management. | Unsupported |
| “NPY opposes CRH” | NPY antagonizes CRH-mediated stress responses at multiple levels—reducing CRH expression, inhibiting CRH-induced ACTH release, and counteracting CRH anxiogenic effects. Well-established in animal models and supported by human biomarker data. | Supported |
| “The failure of CRH-R1 antagonists disproves the CRH hypothesis” | The failure may reflect inadequate patient selection (not all depression is CRH-driven), compensatory mechanisms, or inappropriate trial design rather than a fundamentally wrong hypothesis. The biology remains sound. | Unsupported |
| “CRH drives the cortisol awakening response” | CRH contributes to the morning cortisol surge, but the cortisol awakening response is also regulated by the suprachiasmatic nucleus (circadian clock) and adrenal sensitivity. CRH is one input, not the sole driver. | Mixed Evidence |
| “Chronic stress permanently elevates CRH” | Chronic stress can upregulate CRH expression and impair feedback inhibition. "Permanently" is too strong—CRH normalization can occur with stress resolution, though prolonged elevation may produce epigenetic changes. | Mixed Evidence |
The Human Evidence Landscape
The human evidence for CRH is unique in Cluster J—extensive but almost entirely observational and diagnostic rather than therapeutic. CRH is one of the best-characterized molecules in human neuroendocrinology. The evidence that it is central to stress, depression, and anxiety is overwhelming. The evidence that modulating it therapeutically helps patients is essentially zero.
Biomarker Evidence — Strong
Nemeroff's 1984 finding of elevated CSF CRH in depression has been replicated across multiple patient populations and centers. CSF CRH elevation correlates with HPA axis hyperactivity, cortisol non-suppression on the dexamethasone suppression test, and symptom severity. Similar findings exist in PTSD, anxiety disorders, and chronic stress states. This body of evidence is not in dispute.
Diagnostic Evidence — Established
The CRH stimulation test (IV corticorelin ovine triflutate, 1 mcg/kg) is an FDA-approved diagnostic procedure for differentiating pituitary-dependent Cushing's disease from ectopic ACTH-producing tumors. Pituitary adenomas respond to CRH with ACTH/cortisol surge; ectopic tumors typically do not. This is clinical standard of care.
Therapeutic Evidence — Failed
The CRH-R1 antagonist program represents one of the most expensive therapeutic failures in psychiatric drug development: - Pexacerfont (Bristol-Myers Squibb): Phase III trial for generalized anxiety disorder—failed to separate from placebo - Verucerfont (GlaxoSmithKline): Phase II—discontinued for insufficient efficacy - CP-154,526 (Pfizer): Preclinical/early clinical—hepatotoxicity concerns - Antalarmin (NIMH): Research tool compound, never advanced to clinical trials - SSR-125543 (Sanofi): Phase II depression—discontinued
Total investment across pharmaceutical companies: estimated in the hundreds of millions of dollars. Total approved products: zero.
Why They Failed — The Unanswered Question
The failure of CRH-R1 antagonists is not settled science. Proposed explanations include: biological heterogeneity of depression (only a CRH-overactive subgroup would respond), compensatory upregulation of alternative pathways (urocortins via CRH-R2, AVP via V1b), inadequate CNS penetration of the antagonists, wrong clinical trial design (standard depression scales may not capture the specific symptoms CRH-R1 antagonism would relieve), and the possibility that CRH excess is a consequence rather than a cause of depression.
Recent thinking has shifted toward biomarker-selected trials—identifying the subset of depressed patients with documented CRH/HPA axis hyperactivity and testing CRH-R1 antagonists specifically in that population. This approach has not yet been implemented.
PLAIN ENGLISH
We know CRH is elevated in depression and PTSD—that has been measured and confirmed repeatedly. We know CRH drives the stress response—that is textbook endocrinology. What we do not know is why blocking CRH receptors does not treat depression. Drug companies spent fortunes trying, and every CRH-blocking drug failed in clinical trials. The best current explanation is that depression is not one disease—it is many diseases that look alike—and CRH-blocking drugs might work for the subset of patients whose depression is specifically driven by CRH overactivity. No one has run that trial yet.
Safety, Risks, and Limitations
Diagnostic CRH Administration (Acthrel)
IV bolus CRH (1 mcg/kg corticorelin ovine triflutate) is used in the CRH stimulation test. Known adverse effects: - Facial flushing (16% of patients) - Transient dyspnea and urge to take a deep breath - Transient hypotension - Tachycardia - Rarely: severe hypotension, loss of consciousness - These effects are transient (minutes) and reflect the vasodilatory properties of IV CRH
Theoretical Risks of Exogenous CRH
Administering CRH would be counterproductive for stress management—it activates the very system that produces stress symptoms: - HPA axis activation → cortisol surge - Amygdala CRH-R1 activation → anxiety, fear - Sleep disruption → increased wakefulness, reduced slow-wave sleep - Appetite suppression (acute) → CRH is anorexigenic
There is no therapeutic rationale for exogenous CRH administration outside the diagnostic stimulation test.
CRH-R1 Antagonist Safety
The clinical trials of CRH-R1 antagonists, while failing on efficacy, provided safety data: - Generally well-tolerated at tested doses - Early compounds (CP-154,526) showed hepatotoxicity signals - Later-generation compounds (pexacerfont, verucerfont) had acceptable safety profiles - The clinical development was not stopped for safety reasons but for futility—the drugs were safe but did not work
PLAIN ENGLISH
Taking CRH would make you more stressed, not less—it fires up the exact system you would want to quiet. The diagnostic test where CRH is given by IV is brief and causes temporary flushing and blood pressure changes. The CRH-blocking drugs were actually safe—they just did not help depression or anxiety enough to get approved.
Legal and Regulatory Status
Corticorelin ovine triflutate (Acthrel) is an FDA-approved diagnostic agent for use in Cushing's syndrome workup. It is available by prescription for institutional/clinical use only—not for home use or self-administration.
CRH is not available from consumer peptide vendors and is not marketed as a research peptide for self-experimentation. Research-grade human/rat CRH is available from laboratory peptide suppliers (Bachem, Phoenix Pharmaceuticals) for institutional research use.
No CRH receptor antagonist is FDA-approved for any indication. All clinical development programs have been discontinued or are inactive.
WADA does not list CRH on its Prohibited List.
Research Protocols and Formulation Considerations
CRH Stimulation Test (Diagnostic Protocol)
| Parameter | Detail |
|---|---|
| Formulation | Corticorelin ovine triflutate (Acthrel), lyophilized, reconstituted in saline |
| Dose | 1 mcg/kg IV bolus |
| Procedure | Baseline ACTH + cortisol draws → CRH injection → serial blood draws at 15, 30, 45, 60 minutes |
| Interpretation | Pituitary Cushing's: ACTH rise >50%, cortisol rise >20%. Ectopic ACTH: minimal/no response |
| Setting | Hospital/clinic with monitoring capability |
Storage
Research-grade CRH: lyophilized powder at −20°C (−4°F). Reconstituted solutions: 2–8°C (36–46°F), use within 24 hours. CRH is susceptible to proteolytic degradation.
Dosing in Published Research
The following table summarizes dosing protocols for Corticotropin-Releasing Hormone as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.
Published Research Dosing
| Parameter | Detail |
|---|---|
| Route | IV bolus (diagnostic) |
| Diagnostic dose | 1 mcg/kg corticorelin ovine triflutate |
| Research dose (human) | 1–100 mcg IV (neuroendocrine challenge studies) |
| Research dose (animal ICV) | 0.1–10 mcg intracerebroventricular |
| Therapeutic dose | Does not exist — no CRH-based therapeutic is approved or in development |
Dosing in Self-Experimentation Communities
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
WHY IS THIS SECTION NEARLY EMPTY?
Corticotropin-Releasing Hormone has limited community usage data. Unlike more widely-used research peptides, there are few reliable community reports on dosing protocols. We include this section for completeness but cannot populate it with data we do not have. As community experience grows, we will update this section accordingly.
Why This Section Is Nearly Empty
CRH is not used in self-experimentation communities. Administering exogenous CRH would activate the stress response—the opposite of what anyone seeking stress relief or sleep improvement wants. CRH has no recreational, nootropic, or wellness application. The interest in CRH is entirely conceptual: understanding how the stress system works, not supplementing a stress-activating hormone. No peptide vendor sells CRH for consumer use.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into Corticotropin-Releasing Hormone combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining Corticotropin-Releasing Hormone with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
Related Compounds: How Corticotropin-Releasing Hormone Compares
Corticotropin-Releasing Hormone belongs to a broader family of compounds being investigated for similar applications. The table below compares key characteristics across related compounds in the Sleep, Stress & Recovery cluster.
Mechanistic overlap does not imply equivalent evidence. Each compound has a distinct research profile, regulatory status, and level of clinical validation.
| Compound | Type | Evidence Tier | Verdict | Primary Mechanism | Primary Application | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|
| Neuropeptide Y | Neuropeptide (36 aa) | Tier 2 — Clinical Trials | Eyes Open | Y1 receptor anxiolysis, CRH antagonism, HPA axis modulation | Stress resilience, PTSD, anxiety | Phase Ib RCT (intranasal, PTSD) + RCT (MDD) — ~54 patients total | Not approved | Not prohibited | Small early-phase trials; intranasal BBB penetration uncertain |
| Desmopressin | Synthetic vasopressin analog (9 aa, cyclic) | Tier 1 — Approved Drug | Strong Foundation | V2 receptor agonism → antidiuresis → reduced nocturnal urine volume | Nocturnal enuresis, nocturia, central DI | Cochrane review (47 RCTs, N=3,448) + Phase III nocturia (N=757) | Approved (multiple formulations, 1978+) | Not prohibited | Hyponatremia risk; nasal spray withdrawn for enuresis (2007) |
| Corticotropin-Releasing Hormone | Neuropeptide (41 aa) | Tier 4 — Preclinical (therapeutic) | Eyes Open | HPA axis master switch — CRH-R1 activation → ACTH → cortisol | Understanding stress biology; CRH-R1 antagonists for depression (failed) | Biomarker studies (elevated CSF CRH in depression); CRH-R1 antagonist trials failed | Diagnostic only (Acthrel for Cushing's differentiation) | Not prohibited | CRH-R1 antagonists failed in depression trials despite strong mechanistic rationale |
| Orexin | Neuropeptide pair (OxA 33 aa + OxB 28 aa) | Tier 1 — Approved Drug | Strong Foundation | OX1R/OX2R wake promotion; loss → narcolepsy | Insomnia (via DORAs); narcolepsy diagnosis/treatment | 3 Phase III DORA trials (N=4,945 total); CSF orexin diagnostic for narcolepsy | 3 DORAs approved (suvorexant 2014, lemborexant 2019, daridorexant 2022) | Not prohibited (DORAs may be relevant) | DORAs are small molecules not peptides; orexin agonists for narcolepsy still in development |
| Cortistatin | Neuropeptide (14–17 aa, somatostatin-related) | Tier 4 — Preclinical Only | Eyes Open | Cortical activity depression → slow-wave sleep induction; ACh antagonism | Deep sleep promotion (theoretical) | None | Not approved | Not prohibited | No human data; single research group; somatostatin receptor cross-reactivity |
| Galanin | Neuropeptide (29 aa) | Tier 3 — Limited Human Data | Eyes Open | VLPO sleep-switch activation; LC noradrenergic inhibition | Sleep initiation; potential antidepressant | 1 IV study in healthy men: increased REM, preliminary antidepressant signal | Not approved | Not prohibited | Single small human study; 3 receptor subtypes with opposing effects complicate targeting |
| PACAP | Neuropeptide (27–38 aa, VIP family) | Tier 2 — Clinical Trials | Eyes Open | PAC1/VPAC receptor activation → stress amplification + migraine | Migraine prevention (via anti-PAC1 antibody); PTSD genetics | Phase 2 anti-PAC1 antibody (migraine, positive); PTSD genetic association | Not approved (anti-PAC1 Lu AG09222 Phase 2b ongoing) | Not prohibited | Therapeutic = blocking PACAP not administering it; stress/sleep applications undeveloped |
| Melanin-Concentrating Hormone | Neuropeptide (19 aa) | Tier 4 — Preclinical Only | Eyes Open | MCH neuron activation → selective REM sleep promotion | REM sleep regulation; narcolepsy (MCHR1 antagonism) | None clinical | Not approved; HBS-102 IND stage (narcolepsy) | Not prohibited | No human clinical data; obesity MCHR1 programs failed; narcolepsy IND not advanced |
| Cosyntropin | Synthetic ACTH fragment (24 aa) | Tier 1 — Approved Drug | Strong Foundation | MC2R activation → adrenal cortisol production | Adrenal insufficiency diagnosis (ACTH stimulation test) | Millions of diagnostic tests performed worldwide since 1970 | Approved diagnostic (Cortrosyn, 1970). Synacthen Depot therapeutic (EU/UK). | Prohibited (S2 — ACTH analogs) | US diagnostic only; therapeutic use primarily outside US |
Frequently Asked Questions
Summary of Key Findings
Corticotropin-releasing hormone is the molecule at the top of the human stress response—the 41-amino-acid peptide that tells your pituitary to release ACTH, which tells your adrenals to release cortisol. Its discovery in 1981 by Wylie Vale was one of the landmark achievements in neuroendocrinology, and the subsequent finding that CRH is elevated in the spinal fluid of depressed patients made it one of the most compelling drug targets in psychiatric history.
The clinical story of CRH is a cautionary tale about the gap between knowing how a system works and knowing how to fix it. The biology is bulletproof: CRH drives the stress response, is overactive in depression and PTSD, disrupts sleep, promotes anxiety, and is physiologically opposed by NPY. The pharmacology followed logically: block CRH-R1, normalize the overactive stress axis, treat depression. Multiple pharmaceutical companies developed CRH-R1 antagonists. Every one failed in clinical trials—not because the drugs were unsafe, but because they did not produce clinically meaningful improvement in depression or anxiety symptoms.
The failure is not a refutation of CRH biology. It is a demonstration of something the field increasingly recognizes: depression is not one disease. CRH hyperactivity may drive a subset of cases—perhaps those with documented HPA axis dysregulation—but testing drugs in all comers dilutes the signal. The precision-psychiatry approach—selecting patients by CRH biomarker status before treating—has not yet been implemented but represents the most likely path forward.
For Peptidings readers, CRH is best understood as a map of the stress system rather than a therapeutic target. It explains why chronic stress produces cortisol excess, why PTSD involves measurable neurochemical changes, why depression disrupts sleep in characteristic patterns, and why NPY—CRH's natural counterweight—has generated interest as a resilience molecule. Understanding CRH is understanding stress biology at its source.
Verdict Recapitulation
Evidence Tier 4 — Preclinical Only. CRH is extensively characterized in humans as a biomarker and diagnostic tool, but no therapeutic application has achieved clinical proof of concept.
Verdict: Eyes Open. The biology is among the most compelling in neuroscience. The therapeutic translation failed. Understanding why it failed may be more valuable than the drugs that never worked.
For readers considering Corticotropin-Releasing Hormone, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source Corticotropin-Releasing Hormone
Further Reading and Resources
If you want to go deeper on Corticotropin-Releasing Hormone, the evidence landscape for sleep, stress & recovery peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Sleep, Stress & Recovery Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: Corticotropin-Releasing Hormone — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Vale W, et al. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science. 1981;213(4514):1394–1397 PubMed
- Nemeroff CB, et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science. 1984;226(4680):1342–1344 PubMed
- Holsboer F, Ising M. Stress hormone regulation: biological role and translation into therapy. Annu Rev Psychol. 2010;61:81–109 PubMed
- Risbrough VB, Stein MB. Role of corticotropin releasing factor in anxiety disorders: a translational research perspective. Horm Behav. 2006;50(4):550–561 PubMed
- Bale TL, Vale WW. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol. 2004;44:525–557 PubMed
- Arborelius L, et al. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol. 1999;160(1):1–12 PubMed
- Henckens MJ, et al. CRF receptor type 2 neurons in the posterior bed nucleus of the stria terminalis critically contribute to stress recovery. Mol Psychiatry. 2017;22(12):1691–1700 PubMed
- Heim C, Nemeroff CB. The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. Biol Psychiatry. 2001;49(12):1023–1039 PubMed
DISCLAIMER
Corticotropin-Releasing Hormone is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 09, 2026. Next scheduled review: October 06, 2026.